Biocad plans to launch biosimilar of Humira in Russia

15 March 2019

Russian‘s leading drugmaker Biocad has registered a biosimilar of Humira(adalimumab), the world’s best-selling drug, used for the treatment of rheumatoid arthritis and psoriasis, among other inflammatory conditions, according to the company.

Despite the fact that AbbVie’s (NYSE: ABBV) Humira, whose sales worldwide reached almost $20 billion in 2018, may be protected by a patent, the Russian company intends to bring its biosimilar to the market as early as 2019, reports The Pharma Letter’s local correspondent. After this happens, AbbVie, as well as its Russian supplier R-Pharm, may lose sales on the Russian market.

The new biosimilar registered by Biocad is known as Dalibra. According to the Russian company, all its stages of production, including the production of active ingredients, will be carried out at the facilities of Biocad in the Moscow region.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK